Dr. Ahmed A. Refae

Consultant Oncology

Consultant Clinical Oncology
International Medical Ceneter-Jeddah

17 : 35 – 17 : 45

23 June | 2023 Day 1

KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.

4th PSMMC ASCO Data Review Meeting (PADRM). This meeting will highlight the top most clinically relevant achievements of ASCO 2023 for different and commonest tumor types.